OTC · Biotechnology

Noxopharm Limited (NOXOF) Stock

$0.05 +0.00% OTC: NOXOF Healthcare

Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatment of late-stage cancers.

Valuation

MetricValue
Price$0.05
Market Cap$14.78M
P/E Ratio-5.00
P/B Ratio2.96
P/S Ratio7.39
EPS (TTM)$-0.01
52-Week High$0.05
52-Week Low$0.05
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-80.00%
ROA-57.14%
ROCE798.35%
Gross Margin-400.00%
Operating Margin-400.00%
Net Margin-200.00%
Debt/Equity0.00
Current Ratio5.00

Annual Financials (USD)

Metric20202021202220232024
Revenue$8.0M$6.0M$5.0M$6.0M$2.0M
Operating Profit$-16.0M$-15.0M$-15.0M$-17.0M$-8.0M
Net Profit$0$-9.0M$-19.0M$-15.0M$-4.0M
EPS$0.00$-0.04$-0.06$-0.05$-0.01
Op Margin-197.6%-260.5%-280.1%-276.1%-313.9%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$20.0M$48.0M$27.0M$10.0M$7.0M
Total Liabilities$7.0M$7.0M$2.0M$1.0M$1.0M
Cash$7.0M$27.0M$14.0M$3.0M$2.0M
Borrowings$5.0M$0$0$0$0

Latest News

Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases PR Newswire · Jul 23, 2026 Video: USF Athletics and Tampa General Hospital Unveil New Football Uniforms Featuring Tampa General Hospital Patch PR Newswire · Jul 23, 2026 Argentine Football Association says US did not detain its president AFP · Jul 23, 2026 Dow Jones Futures Rise; Google, Tesla Fall On Earnings, Capex, But AI Stocks Climb Investor's Business Daily · Jul 23, 2026 HD Hyundai Heavy Industries Reaches Major Milestone in ITER Nuclear Fusion Project PR Newswire · Jul 23, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-11.0M$-9.0M$-14.0M$-11.0M$-1.0M
Investing Cash Flow$1.0M$0$0$0$0
Financing Cash Flow$1.0M$0$0$0$-2.0M
Net Cash Flow$4.0M$20.0M$-13.0M$-11.0M$-1.0M
Free Cash Flow$-11.0M$-9.0M$-14.0M$-11.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA-4.98
FCF Yield-27.53%
Quick Ratio0.81
Interest Coverage-9.52
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMHVAmerican Hemp Ventures, Inc. $0.98 +0.00% — $16.47M 0.00%
CRPOFCeapro Inc. $0.17 -13.04% -3.74 $13.31M 0.00%
EIGRQEiger BioPharmaceuticals, Inc. $8.50 +6.25% -0.17 $12.59M 0.00%
MNNDFNurosene Health Inc. $0.33 -8.71% -0.82 $14.25M 0.00%
NXTTFLifeist Wellness Inc. $0.04 -3.64% 14.29 $15.76M 0.00%

About Noxopharm Limited

Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatment of late-stage cancers. The company's robust pipeline includes several programs: The DARRT program, currently in Phase 1b/2a, targets metastatic castration-resistant prostate cancer and other solid tumor types. LuPIN investigates a combined therapy of Veyonda with 177Lu-PSMA-617 for managing late-stage prostate cancer. The IONIC program explores Veyonda in combination with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, for various solid tumor indications. Its Chemotherapy Enhancement Program (CEP) utilizes Veyonda alongside carboplatin to treat refractory solid tumors found in the breast, head and neck, lung, prostate, and ovaries. Beyond oncology, Noxopharm is advancing the NOXCOVID Program, a dose escalation and expansion study of NOX66, aimed at treating COVID-19 infections. Additionally, the company is pursuing early-stage programs for pancreatic cancer and glioblastoma. Noxopharm Limited has established a collaboration with the Hudson Institute of Medical Research and The Australian National University to conduct research and development into therapeutic drugs for inflammatory disorders. Founded in 2015, the company is based in Chatswood, Australia.

Noxopharm Limited (NOXOF) stock trades at $0.05 with a market capitalization of $14.78M. The stock is valued at a price-to-earnings (P/E) ratio of -5.00, price-to-book of 2.96, price-to-sales of 7.39. Over the past 52 weeks the stock has ranged between $0.05 and $0.05, and currently trades at its 52-week high.

On profitability, Noxopharm Limited generates a return on equity (ROE) of -80.00%, return on capital employed of 798.35%, an operating margin of -400.00%, a net profit margin of -200.00%.

Official website: www.noxopharm.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides